Evidence map›Paper›PMID 19465903›Full record

ArticleModern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc2009

Characterization of ETS gene aberrations in select histologic variants of prostate carcinoma.

Bo Han, Rohit Mehra, Khalid Suleman, Scott A Tomlins, Lei Wang, Nishi Singhal, Katherine A Linetzky, Nallasivam Palanisamy, Ming Zhou, Arul M Chinnaiyan and 1 more

Open access · bronzeAbstract read
In one paragraph

Article in Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed
6.9field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 102 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Molecular Biomarkers in the Clinical Management of Prostate Cancer.Cold Spring Harbor perspectives in medicine · 2018
    Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Integrative molecular profiling of routine clinical prostate cancer specimens.Annals of oncology : official journal of the European Society for Medical Oncology · 2015
    Article
  17. Article
  18. Aggressive variants of castration-resistant prostate cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2014
    Review
  19. Article
  20. Small cell carcinoma of the prostate.Nature reviews. Urology · 2014
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 1 country.

Bo HanMichigan Center for Translational Pathology, University of Michigan Medical School, Ann Arbor, MI 48109, USA.
Rohit Mehra
Khalid Suleman
Scott A Tomlins
Lei Wang
Nishi Singhal
Katherine A Linetzky
Nallasivam Palanisamy
Ming Zhou
Arul M Chinnaiyan
Rajal B Shah
University of Michigan–Ann Arbor · USMichigan Center for Translational Pathology · USCleveland Clinic · USHoward Hughes Medical Institute · US

Funding

VACCINIA PSA FOR ANDROGEN-MODULATED POST-SURGICAL RECURRENCE OF PROSTATE CANCERP50CA069568 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI COONEY, KATHLEEN A · 1995 to 2013
$31.3M
Epitomic Biomarkers of Prostate CancerU01CA111275 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI CHINNAIYAN, ARUL M, RUBIN, MARK A. · 2004 to 2015
$6.8M
Molecular Changes Associated with PCa bone metastasesR01CA102872 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI PIENTA, KENNETH J. · 2003 to 2006
$1.3M
NCI NIH HHS P50 CA069568NCI NIH HHS P50CA69568NCI NIH HHS R01 CA102872NCI NIH HHS U01 CA111275NCI NIH HHS UO1 CA111275-01
6 · The paper itself

Abstract

Histologic variants of prostate carcinoma account for 5-10% of the disease and are typically seen in association with conventional acinar carcinoma. These variants often differ from the latter in clinical, immunophenotypic, and biologic potential. Recently, recurrent gene fusions between the androgen-regulated gene TMPRSS2 and the ETS transcription factors ERG, ETV1, ETV4, or ETV5 have been identified in a majority of conventional prostate carcinomas. However, the frequency and significance of this critical molecular event is unknown in the histologic variants of prostate carcinoma. Here, we used break-apart fluorescence in situ hybridization to assess TMPRSS2 and ETS aberrations in a series of select histologic variants: foamy gland carcinoma (N=17), ductal adenocarcinoma (N=18), mucinous carcinoma (N=18), and small cell carcinoma (N=7). A histologic variation of acinar adenocarcinoma, demonstrating glomeruloid morphology (N=9), was also investigated. Overall, 55% of histologic variant or variation morphologies demonstrated ETS aberrations (ERG in 54% and ETV1 in 1%). TMPRSS2:ERG fusion was identified in 83% (15/18), 71% (5/7), 50% (9/18), 33% (3/9), and 29% (5/17) of mucinous, small cell, ductal, glomeruloid, and foamy gland prostate carcinomas, respectively. Previously, we reported that 100% of androgen-independent metastatic prostate carcinomas harboring TMPRSS2:ERG gene fusion were associated with interstitial deletion (Edel). Interestingly, ERG rearrangement in small cell carcinomas occurred exclusively through Edel, supporting the notion that TMPRSS2:ERG with Edel is an aggressive molecular subtype. SPINK1, a biomarker expressed exclusively in a subset of ETS negative prostate carcinomas, was expressed in 6% of ETS negative histologic variants, specifically in ductal adenocarcinoma. Notably, 88% (43/49) variant morphologies in this cohort showed concordance of TMPRSS2:ERG fusion with associated conventional acinar type, suggesting that variant morphology is clonally related to the latter. Overall, our data provide insight into the origin, molecular mechanism, and phenotypic association of ETS fusions in histologic variants of prostate carcinoma.

Indexed as

AgedBiomarkers, TumorCarcinomaCarrier ProteinsChromosome AberrationsGene Expression Regulation, NeoplasticHumansIn Situ Hybridization, FluorescenceMaleMiddle AgedNeoplasm StagingOncogene Proteins, FusionProstatic NeoplasmsProto-Oncogene Proteins c-etsReverse Transcriptase Polymerase Chain ReactionTissue Array AnalysisBiomarkers, TumorCarrier ProteinsOncogene Proteins, FusionProto-Oncogene Proteins c-etsSPINK1 protein, humanTMPRSS2-ERG fusion protein, humanTMPRSS2-ETV1 fusion protein, humanTrypsin Inhibitor, Kazal Pancreatic

Identifiers

PMID19465903
PMCPMC2760291
OpenAlexW2062908914

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.